← Back to search
ELIGO BIOSCIENCE
PARIS 13
UnclaimedClaim this profile (free)
Subcontracting experience
1 record from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | IT IS NOW WELL ACCEPTED THAT THE COMMENSAL BACTERIA THAT RESIDE IN OUR INTESTINES (COLLECTIVELY CALLED THE INTESTINAL MICROBIOTA) PLAY A KEY ROLE IN HEALTH: THEY HELP US DIGEST FOOD, BRING US ESSENTIAL NUTRIENTS AND ARE INSTRUMENTAL IN FIGHTING AGAINST PATHOGENS.
NEVERTHELESS, IN A CONTEXT OF RISING RESISTANCE TO ANTIBIOTICS THE INTESTINAL MICROBIOTA CAN ALSO SERVE AS A RESERVOIR FOR MULTI-DRUG RESISTANT (MDR) BACTERIA, SUCH AS ESBL AND CR ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE. WHILE SUCH INTESTINAL COLONIZATION WITH ESBL/CR E. COLI AND K. PNEUMONIAE REMAIN ASYMPTOMATIC FOR MOST HEALTHY PEOPLE, IT CAN HAVE DRAMATIC CONSEQUENCES FOR PATIENTS THAT ARE AT RISK OF DEVELOPING INFECTIONS.
PATIENTS UNDERGOING SOLID ORGAN TRANSPLANTATION (SOT) ARE PARTICULARLY AT RISK OF DEVELOPING INFECTIONS AS HARSH CONDITIONING (IMMUNOSUPPRESSION, ANTIBIOTIC PROPHYLAXIS) AND INVASIVE PROCEDURES (SURGERY) INCREASE THE CHANCE FOR INTESTINAL BACTERIA TO DISSEMINATE OUT OF THE INTESTINE AND CAUSE AN INFECTION. IN FACT, SOT PATIENTS WHOSE INTESTINES ARE COLONIZED WITH ESBL/CR E. COLI AND K. PNEUMONIAE WERE SHOWN TO BE PARTICULARLY AT RISK OF CONTRACTING MDR INFECTIONS CAUSED BY THE SAME ORGANISMS IN THE WEEKS FOLLOWING THE SOT PROCEDURE.
TO ADDRESS THIS THREAT, ELIGO BIOSCIENCE IS DEVELOPING EB004, THE FIRST PROGRAMMABLE HIGHLY SPECIFIC ANTIMICROBIAL TO ELIMINATE ESBL AND CR E. COLI AND K. PNEUMONIAE FROM THE MICROBIOTA OF SOT PATIENTS BEFORE THE SOT PROCEDURE AND THEREBY PREVENT THE ONSET OF LETHAL INFECTIONS. THIS TECHNOLOGY RELIES ON EXTREMELY EFFICIENT DNA DELIVERY VECTORS DERIVED FROM BACTERIOPHAGES PROGRAMMED TO DELIVER A SYNTHETIC DNA PAYLOAD DIRECTLY INTO THE TARGET ESBL/CR E. COLI AND K. PNEUMONIAE IN THE PATIENT€„¢S GASTROINTESTINAL TRACT. THE DNA PAYLOAD ENABLES THE EXPRESSION OF A CAS RNA-GUIDED NUCLEASE COMPLEX FROM TYPE II CRISPR SYSTEMS PROGRAMMED TO CREATE DOUBLE STRAND BREAKS ONLY IN GENES CARRIED BY ESBL/CR E. COLI AND K. PNEUMONIAE ONLY. BACTERIA THAT CARRY THESE GENES ARE THEREFORE EITHER ELIMINATED OR RE-SENSITIZED ANTIBIOTICS (DEPENDING ON THE LOCATION OF THE GENES). PATIENTS€„¢ COMMENSAL BACTERIA THAT DO NOT CARRY THESE RESISTANCE GENES, INCLUDING MUTUALISTIC/BENEFICIAL E. COLI, ARE LEFT UNHARMED.
OVERALL, THE EB004 PRODUCT DEVELOPED BY ELIGO BIOSCIENCE AND SUPPORTED BY CARB-X AIMS AT CURING ANTIBIOTIC RESISTANCE FROM THE MICROBIOTA OF PATIENTS AT RISK OF DEVELOPING SERIOUS AND DIFFICULT-TO-TREAT INFECTIONS TO IMPROVE PATIENT CARE, ANTIBIOTIC STEWARDSHIP AND PATIENT PROGNOSIS WITHOUT DISRUPTING THE PATIENT€„¢S HEALTHY MICROBIOTA. 4500004460 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $34,517 | Feb 1, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.